Ad is loading...
GLMD
Price
$2.93
Change
-$0.17 (-5.48%)
Updated
Nov 15 closing price
One day until earnings call
XBIO
Price
$3.69
Change
+$0.03 (+0.82%)
Updated
Nov 15 closing price
Ad is loading...

GLMD vs XBIO

Header iconGLMD vs XBIO Comparison
Open Charts GLMD vs XBIOBanner chart's image
Galmed Pharmaceuticals
Price$2.93
Change-$0.17 (-5.48%)
Volume$35.56K
CapitalizationN/A
Xenetic Biosciences
Price$3.69
Change+$0.03 (+0.82%)
Volume$2.7K
CapitalizationN/A
GLMD vs XBIO Comparison Chart
Loading...
GLMD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
XBIO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
GLMD vs. XBIO commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLMD is a Sell and XBIO is a StrongSell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (GLMD: $2.93 vs. XBIO: $3.69)
Brand notoriety: GLMD and XBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GLMD: 1% vs. XBIO: 12%
Market capitalization -- GLMD: $4.42M vs. XBIO: $5.69M
GLMD [@Biotechnology] is valued at $4.42M. XBIO’s [@Biotechnology] market capitalization is $5.69M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLMD’s FA Score shows that 0 FA rating(s) are green whileXBIO’s FA Score has 1 green FA rating(s).

  • GLMD’s FA Score: 0 green, 5 red.
  • XBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, XBIO is a better buy in the long-term than GLMD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLMD’s TA Score shows that 2 TA indicator(s) are bullish while XBIO’s TA Score has 2 bullish TA indicator(s).

  • GLMD’s TA Score: 2 bullish, 5 bearish.
  • XBIO’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, both GLMD and XBIO are a bad buy in the short-term.

Price Growth

GLMD (@Biotechnology) experienced а -1.35% price change this week, while XBIO (@Biotechnology) price change was -1.86% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

GLMD is expected to report earnings on Nov 18, 2024.

XBIO is expected to report earnings on Aug 11, 2023.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XBIO($5.69M) has a higher market cap than GLMD($4.42M). XBIO YTD gains are higher at: 6.953 vs. GLMD (-46.337). XBIO has higher annual earnings (EBITDA): -5.01M vs. GLMD (-6.15M). GLMD has more cash in the bank: 9.82M vs. XBIO (7.3M). GLMD has less debt than XBIO: GLMD (41K) vs XBIO (153K). XBIO has higher revenues than GLMD: XBIO (2.52M) vs GLMD (0).
GLMDXBIOGLMD / XBIO
Capitalization4.42M5.69M78%
EBITDA-6.15M-5.01M123%
Gain YTD-46.3376.953-666%
P/E RatioN/AN/A-
Revenue02.52M-
Total Cash9.82M7.3M135%
Total Debt41K153K27%
FUNDAMENTALS RATINGS
GLMD vs XBIO: Fundamental Ratings
GLMD
XBIO
OUTLOOK RATING
1..100
5927
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
17
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9595
PRICE GROWTH RATING
1..100
8748
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
7585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XBIO's Valuation (17) in the Biotechnology industry is in the same range as GLMD (39) in the Pharmaceuticals Other industry. This means that XBIO’s stock grew similarly to GLMD’s over the last 12 months.

XBIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as GLMD (100) in the Pharmaceuticals Other industry. This means that XBIO’s stock grew similarly to GLMD’s over the last 12 months.

XBIO's SMR Rating (95) in the Biotechnology industry is in the same range as GLMD (95) in the Pharmaceuticals Other industry. This means that XBIO’s stock grew similarly to GLMD’s over the last 12 months.

XBIO's Price Growth Rating (48) in the Biotechnology industry is somewhat better than the same rating for GLMD (87) in the Pharmaceuticals Other industry. This means that XBIO’s stock grew somewhat faster than GLMD’s over the last 12 months.

XBIO's P/E Growth Rating (100) in the Biotechnology industry is in the same range as GLMD (100) in the Pharmaceuticals Other industry. This means that XBIO’s stock grew similarly to GLMD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GLMDXBIO
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
81%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
79%
MACD
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
83%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
86%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
N/A
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
View a ticker or compare two or three
Ad is loading...
GLMD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
XBIO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
JBLU7.06-0.05
-0.70%
JetBlue Airways Corp
GNPX1.60-0.04
-2.44%
Genprex
NTRA146.06-5.05
-3.34%
Natera
MNTK4.12-0.19
-4.41%
Montauk Renewables
EBS7.72-1.55
-16.72%
Emergent Biosolutions

GLMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLMD has been closely correlated with XBIO. These tickers have moved in lockstep 88% of the time. This A.I.-generated data suggests there is a high statistical probability that if GLMD jumps, then XBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLMD
1D Price
Change %
GLMD100%
-5.48%
XBIO - GLMD
88%
Closely correlated
+0.82%
IOBT - GLMD
37%
Loosely correlated
-7.87%
RCKT - GLMD
32%
Poorly correlated
-5.67%
LBPH - GLMD
31%
Poorly correlated
-0.08%
JSPR - GLMD
31%
Poorly correlated
-7.56%
More

XBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, XBIO has been loosely correlated with SYRE. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if XBIO jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XBIO
1D Price
Change %
XBIO100%
+0.82%
SYRE - XBIO
34%
Loosely correlated
-6.62%
VXRT - XBIO
29%
Poorly correlated
-7.92%
EDSA - XBIO
29%
Poorly correlated
-4.55%
CDTX - XBIO
28%
Poorly correlated
-0.76%
AUTL - XBIO
27%
Poorly correlated
+2.33%
More